German CDMO will build new manufacturing capabilities at CGT Catapult site
News
UK government proposes reforms for health and social care following pandemic
Future reforms will aim to bring health and care services closer together
Novo Nordisk’s semaglutide cuts body weight in large-scale trial
Participants lost on average 14.9% of their baseline body weight
WHO panel recommends AZ/Oxford’s COVID-19 vaccine
WHO’s SAGE panel backs wide use of jab in adults, including in people aged over 65
Synairgen’s inhaled COVID-19 treatment included in US trial
Trial is sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID)
NIHR funds study aiming to improve the lives of people with cystic fibrosis
The CF STORM trial will seek to address how the treatment burden for people with CF can be reduced
US approval for Libtayo in advanced basal cell carcinoma
First immunotherapy indicated for certain BCC patients
ViiV’s Rukobia wins EU authorisation to treat multidrug-resistant HIV
Rukobia is a first-in-class HIV attachment inhibitor
EU approves expanded use of Janssen’s Spravato
Treatment authorised for rapid reduction of depressive symptoms in a psychiatric emergency
Antibiotic Research UK calls for clear guidance on the use of antibiotics and COVID-19 vaccines
Charity has urged the UK government to provide clarity on whether people receiving antibiotics can receive a COVID-19 vaccination
Entries now open for the Patient Partnership Index 2021
The Patient Partnership Index 2021 provides a unique opportunity for UK and global pharmaceutical companies to showcase, benchmark and measure the quality and impact of their advocacy with patient groups
The Stroke Association to fund study investigating strokes caused by COVID-19
The research forms part of the CVD-COVID-UK flagship project consortium
SMC approves funding for four new medicines on the NHS
BMS’ MS therapy Zeposia and AbbVie’s JAK inhibitor Rinvoq among latest approvals
AZ’s Imfinzi fails to improve overall survival in head and neck cancer again
Immunotherapy has previously failed in this therapy area
Jazz Pharmaceuticals to acquire GW Pharma for $7.2bn
Jazz will add GW’s plant-derived cannabinoid treatment Epidiolex to its roster
